Improving Durability of Drugs in Wet AMD
Monthly or bimonthly anti-VEGF use poses significant time and cost burden due to the disease’s chronic nature and limited medication half-life. Further potential solutions to address the need for long-acting and more durable therapies include high-concentration anti-VEGF drugs, sustained-release devices, intravitreal reservoirs, suprachoroidal delivery, and gene therapy biofactories.